United States Patent 7,939,502: Tobramycin Aerosol Formulation Claims, Scope, and Patent Landscape

U.S. Patent No. 7,939,502 protects a specific method of treating Pseudomonas aeruginosa lung infection with a preservative-free, antioxidant-free aerosol formulation containing 75 mg/mL tobramycin in 0.45% sodium chloride. The claims narrow progressively around pH and osmolarity, with the tightest dependent claim requiring osmolarity of 314 to 350 mOsm/L. The patent is a formulation and method-of-use patent, not a broad composition claim covering every inhaled tobramycin product.

What does U.S. Patent 7,939,502 claim?

Claim 1 requires every one of the following elements:

Claim element	Requirement
Therapeutic use	Treatment of a lung infection
Pathogen	Pseudomonas aeruginosa
Administration	Administration to a subject in need
Dosage form	Aerosol formulation
Active ingredient	Tobramycin
Tobramycin concentration	75 mg/mL
Vehicle	Aqueous solution
Sodium chloride	0.45% w/v
pH	4.5 to 5.5
Osmolarity	250 to 450 mOsm/L
Excipients excluded	No preservatives and no antioxidants
Dose language	An effective amount

The claim does not expressly require a particular nebulizer, aerosol particle size, inhalation schedule, vial volume, administration frequency, or disease subtype such as cystic fibrosis. Those limitations may appear in the specification, prosecution history, product labeling, or separate patents, but they are not stated in the supplied claims.

The claim is therefore defined by the intersection of composition, physical properties, formulation exclusions, pathogen, and therapeutic administration.

How do the dependent claims narrow patent coverage?

Claims 2 through 9 narrow claim 1 through pH and osmolarity limitations.

Claim	Additional limitation
2	pH is 5.2; osmolarity is 280 to 350 mOsm/L
3	Osmolarity is 280 to 350 mOsm/L
4	Osmolarity is 292 to 350 mOsm/L
5	Osmolarity is 293 to 350 mOsm/L
6	Osmolarity is 295 to 350 mOsm/L
7	Osmolarity is 304 to 350 mOsm/L
8	Osmolarity is 311 to 350 mOsm/L
9	Osmolarity is 314 to 350 mOsm/L

Each dependent claim includes all limitations of claim 1. The ranges are nested:

250-450 mOsm/L
280-350 mOsm/L
292-350 mOsm/L
293-350 mOsm/L
295-350 mOsm/L
304-350 mOsm/L
311-350 mOsm/L
314-350 mOsm/L

A formulation with osmolarity of 320 mOsm/L falls within claims 1 and 3 through 9, assuming all other limitations are met. A formulation at 300 mOsm/L falls within claims 1 and 3 through 6, but not claims 7 through 9. A formulation at 360 mOsm/L falls within none of claims 2 through 9, but may remain within claim 1 if the other limitations are satisfied.

What is the likely patent construction of the key terms?

"75 mg/mL of tobramycin"

This is a concentration limitation. A product materially above or below 75 mg/mL presents a literal infringement issue. The legal analysis may depend on measurement tolerance, manufacturing specifications, assay methodology, and whether the stated concentration is nominal or actual.

A 300 mg dose in 4 mL has a nominal concentration of 75 mg/mL. A 300 mg dose in 5 mL has a nominal concentration of 60 mg/mL and would not literally meet the concentration limitation.

"0.45% w/v of sodium chloride"

This requires 0.45 grams of sodium chloride per 100 mL of aqueous solution. It is distinct from a formulation that uses another tonicity agent, no sodium chloride, or a different sodium chloride concentration.

A product containing 0.45% sodium chloride plus other tonicity-adjusting excipients could still satisfy the claim unless those excipients cause the formulation to fail another limitation, such as the osmolarity range or the requirement that it be free of preservatives and antioxidants.

"Aerosol formulation"

The claim requires administration of the formulation as an aerosol. Nebulized delivery would generally fit the ordinary technical meaning of aerosol administration. The claim does not expressly limit the delivery system to jet, ultrasonic, vibrating-mesh, or other nebulizer technology.

A formulation administered intravenously, intramuscularly, orally, or as a non-aerosol nasal product would not satisfy this element.

"Free of preservatives and anti-oxidants"

This is a significant negative limitation. A formulation containing a conventional antimicrobial preservative or antioxidant would create a strong non-infringement position for literal infringement.

The scope depends on claim construction. Trace impurities, degradation products, excipients with incidental antioxidant activity, and manufacturing residues could become relevant. The claim language does not define a numerical threshold for "free of."

"Pseudomonas aeruginosa infection"

This pathogen limitation narrows the claimed method. Treatment of a lung infection caused solely by another organism would not literally satisfy the claim. Mixed infections may raise a fact-specific issue if P. aeruginosa is among the pathogens being treated.

The claim does not expressly require chronic infection, acute infection, cystic fibrosis, bronchiectasis, or a particular bacterial susceptibility profile.

"Effective amount"

"Effective amount" is a functional limitation tied to treatment of the claimed infection. It is unlikely to require a particular milligram dose unless the specification, prosecution history, or associated claims supply that restriction.

What product characteristics create the highest infringement risk?

A competing inhaled tobramycin product presents the greatest literal infringement risk when it matches the following profile:

Risk factor	High-risk profile
Active ingredient	Tobramycin
Concentration	75 mg/mL
Sodium chloride	0.45% w/v
pH	4.5 to 5.5
Osmolarity	250 to 450 mOsm/L
Preservatives	None
Antioxidants	None
Delivery	Aerosol or nebulized administration
Indication	P. aeruginosa lung infection

A product matching 75 mg/mL, 0.45% sodium chloride, pH 5.2, and osmolarity of approximately 314 to 350 mOsm/L would implicate the full claim set, including claim 2 and claims 8 and 9.

What design-around strategies are available?

Potential design-around positions arise from changing one or more mandatory limitations.

Concentration design-arounds

A formulation at 60 mg/mL or 80 mg/mL would not literally satisfy the 75 mg/mL limitation. The commercial and therapeutic consequences would need separate evaluation because a change in concentration may require a different dose volume, device configuration, or regulatory submission.

Vehicle design-arounds

Replacing 0.45% sodium chloride with another tonicity system could avoid the sodium chloride limitation. A formulation using a different salt concentration may also fall outside the claim.

Osmolarity design-arounds

A formulation outside 250 to 450 mOsm/L would avoid claim 1 on osmolarity grounds. Values below 280 mOsm/L or above 350 mOsm/L would also avoid claims 2 through 9, although formulation tolerability and regulatory acceptability would remain relevant.

pH design-arounds

A pH below 4.5 or above 5.5 would fall outside claim 1. A formulation at pH 5.0 would remain within claim 1 but not claim 2, which requires pH 5.2.

Preservative or antioxidant design-arounds

Adding a qualifying preservative or antioxidant could avoid the negative limitation. This strategy may create separate safety, tolerability, stability, and regulatory issues for inhaled administration.

Therapeutic-use design-arounds

Use for a non-Pseudomonas lung infection would avoid the pathogen limitation. That approach does not eliminate risk under separate method-of-use patents covering other indications or pathogens.

Delivery-system design-arounds

A non-aerosol route could avoid the administration limitation, but it would no longer provide the same pulmonary delivery profile. Changing from nebulized delivery to another aerosol device may not avoid the claim because the claim does not identify a particular aerosol generator.

Design-around analysis must account for the doctrine of equivalents. A change that is immaterial to the claimed technical function may still create litigation risk even when literal infringement is absent.

Is U.S. Patent 7,939,502 a composition patent or a method patent?

It is a method patent based on the supplied claims.

The claims require administration to a subject for treatment of a specified infection. They do not independently claim:

Tobramycin as a chemical compound
A standalone vial or container
The aerosol formulation as a composition
A nebulizer or inhalation device
A manufacturing process
A pharmaceutical kit
A packaging configuration

This distinction affects enforcement. Making or selling a formulation without evidence of intended use may not establish direct infringement of the method claims. Promotional materials, labeling, product instructions, customer targeting, and distribution records can become relevant to induced-infringement theories under 35 U.S.C. § 271(b). Contributory infringement issues may arise under 35 U.S.C. § 271(c) where the product is especially adapted for an infringing use.

What is the relationship between the claims and FDA-approved inhaled tobramycin products?

The claimed profile is associated with a concentrated tobramycin inhalation solution rather than every inhaled tobramycin product.

FDA-approved inhaled tobramycin products have included different concentrations, delivery systems, and formulation presentations. For example, TOBI inhalation solution has historically used a 300 mg dose in a 5 mL unit dose, corresponding to 60 mg/mL, while the claims supplied for U.S. Patent 7,939,502 require 75 mg/mL. A 60 mg/mL product therefore does not literally satisfy the concentration limitation in claim 1.

A product may still face separate patent risk based on:

Nebulizer-device patents
Dry-powder inhaler patents
Capsule or cartridge patents
Formulation-stability patents
Cystic-fibrosis method-of-use patents
Dosing-regimen patents
Manufacturing patents
Packaging and administration-system patents

FDA approval does not determine patent infringement. The Orange Book identifies patents submitted for approved drug products, but it does not provide a complete freedom-to-operate analysis for all formulation, device, process, or method patents. FDA, 2024.

What is the Orange Book and Paragraph IV relevance?

A generic applicant referencing an approved tobramycin inhalation solution could face a Paragraph IV certification if it asserts that an Orange Book-listed patent is invalid, unenforceable, or not infringed. Under the Hatch-Waxman framework, a Paragraph IV notice can trigger patent litigation and a 30-month stay of FDA approval in certain circumstances. 21 U.S.C. § 355(j).

The practical relevance of U.S. Patent 7,939,502 depends on:

Whether it is listed for the relevant reference product.
Whether the proposed generic matches the claimed 75 mg/mL formulation.
Whether the generic label includes treatment of P. aeruginosa lung infection.
Whether the applicant uses a section viii statement to omit a patented indication.
Whether the patent remained in force when the ANDA was filed and when approval was sought.

A generic with a 60 mg/mL formulation could have a stronger non-infringement position against the supplied claims, but it would still need to address any other listed patents.

When does U.S. Patent 7,939,502 lose exclusivity?

The patent's enforceable term depends on its earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers, and any patent-term extension. The issue date alone does not determine expiration. The statutory framework generally provides a term of 20 years from the relevant nonprovisional filing date, subject to adjustments under 35 U.S.C. §§ 154 and 156.

A reliable expiration analysis requires the USPTO patent record and the patent's continuity data. The supplied claims alone do not establish the operative expiration date, any patent-term adjustment, or whether the patent is currently enforceable. The legal status should be checked against the USPTO Patent Center record and the relevant FDA Orange Book entry before relying on the patent for launch planning or litigation strategy.

What other patents are likely to affect inhaled tobramycin competition?

The surrounding patent estate can be divided into several technical categories.

Formulation patents

These may cover:

Tobramycin concentration
Sodium chloride or alternative tonicity agents
pH control
Osmolarity
Preservative-free formulations
Antioxidant-free formulations
Stability during storage
Low-volume unit-dose presentations

Device patents

Device claims may cover:

Jet nebulizers
Vibrating-mesh nebulizers
Aerosol-generation chambers
Dose-delivery controls
Residual-volume reduction
Aerosol particle-size distribution
Breath-actuated systems

Dry-powder patents

Dry-powder products may involve separate rights covering:

Porous particles
Carrier-free powders
Capsule delivery
Blister packaging
Powder dispersion
Inhaler architecture

Method-of-use patents

These may address:

Chronic suppressive therapy
Intermittent dosing cycles
Cystic fibrosis
Bronchiectasis
Resistant P. aeruginosa
Reduction of pulmonary bacterial burden
Treatment in patients with impaired lung function

Manufacturing patents

Manufacturing barriers may cover:

Sterile filling
Tobramycin purification
Control of degradation products
Osmolarity adjustment
Container-closure systems
Nebulizer compatibility
Aseptic production of preservative-free solutions

How strong is the patent estate based on the supplied claims?

The claims have meaningful technical specificity but a narrow literal scope.

Strength factor	Assessment
Claim category	Narrow method-of-treatment claims
Formulation specificity	High
Pathogen specificity	High
Concentration limitation	Restrictive
Device coverage	Limited
Product-by-process coverage	None apparent
Standalone composition coverage	None in supplied claims
Design-around potential	Moderate to high
Enforcement evidence	Depends heavily on labeling and intended use
Vulnerability to invalidity challenge	Depends on prior art and prosecution history

The osmolarity-dependent claims create a tiered fallback structure. If the broad 250 to 450 mOsm/L range is challenged, narrower claims may survive if the record supports the specific subranges. The same narrowing, however, reduces the number of products that fall within the claims.

Potential validity issues would include anticipation, obviousness, written description, enablement, indefiniteness, and claim construction. The strongest validity analysis would require the patent specification, prosecution history, cited references, priority chain, and contemporaneous inhaled tobramycin formulations.

What generic launch scenarios exist?

Scenario 1: 60 mg/mL inhalation solution

A product at 60 mg/mL would not literally meet the 75 mg/mL limitation. It could still face other patents and potential doctrine-of-equivalents arguments, but the supplied claims would present a comparatively weaker barrier.

Scenario 2: 75 mg/mL solution with different osmolarity

A 75 mg/mL formulation using 0.45% sodium chloride but osmolarity below 250 or above 450 mOsm/L would avoid claim 1. A formulation between 250 and 280 mOsm/L would avoid claims 2 through 9 while remaining within claim 1.

Scenario 3: 75 mg/mL solution with a preservative

A formulation containing a qualifying preservative could avoid the "free of preservatives" limitation. Regulatory and pulmonary safety requirements may make this strategy commercially unattractive.

Scenario 4: Same formulation, omitted P. aeruginosa indication

A generic label omitting the patented use may support a section viii strategy if the applicable regulatory and patent-listing requirements are satisfied. Actual infringement exposure would depend on labeling, marketing, prescriber behavior, and other evidence.

Scenario 5: Dry-powder inhalation product

A dry-powder product may avoid the aqueous-solution limitations, but it would enter a separate device and powder patent landscape.

Key Takeaways

U.S. Patent 7,939,502, based on the supplied claims, is a narrow method patent.
Claim 1 requires 75 mg/mL tobramycin, 0.45% w/v sodium chloride, pH 4.5 to 5.5, osmolarity of 250 to 450 mOsm/L, no preservatives, no antioxidants, aerosol delivery, and treatment of P. aeruginosa lung infection.
Claim 2 adds pH 5.2 and osmolarity of 280 to 350 mOsm/L.
Claims 3 through 9 progressively narrow osmolarity, with claim 9 requiring 314 to 350 mOsm/L.
A 60 mg/mL inhaled tobramycin product does not literally satisfy the 75 mg/mL limitation.
The supplied claims do not independently cover nebulizer hardware, dry-powder products, manufacturing methods, or a standalone composition.
Generic risk depends on formulation matching, labeling, intended use, Orange Book listing, and separate device or formulation patents.
Patent expiration cannot be established from the claims alone. USPTO continuity, patent-term adjustment, terminal disclaimers, and Orange Book data control the operative exclusivity analysis.

FAQs

Does a 300 mg dose infringe if it is supplied in 5 mL?

Not on the supplied concentration limitation alone. A 300 mg dose in 5 mL is 60 mg/mL, not 75 mg/mL.

Does a pH of 5.2 automatically implicate claim 2?

No. The formulation must also satisfy every limitation of claim 1 and have osmolarity of 280 to 350 mOsm/L.

Can a product avoid claims 8 and 9 at 310 mOsm/L?

Yes, assuming the other claims are otherwise satisfied. At 310 mOsm/L, the formulation is below the 311 mOsm/L lower limit of claim 8 and the 314 mOsm/L lower limit of claim 9.

Does use against bronchiectasis avoid the patent?

Not necessarily. Bronchiectasis may still involve a P. aeruginosa lung infection. The outcome depends on the actual diagnosis, labeling, treatment purpose, and construction of the pathogen and lung-infection limitations.

Does FDA approval establish that a product is outside the patent?

No. FDA approval and patent infringement are separate determinations. FDA approval confirms regulatory authorization, not freedom to operate.

References

U.S. Patent No. 7,939,502. (2011). United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
21 U.S.C. § 355. (2024). New drugs.
35 U.S.C. § 154. (2024). Contents and term of patent; provisional rights.
35 U.S.C. § 156. (2024). Extension of patent term.
35 U.S.C. § 271. (2024). Infringement of patent.
21 C.F.R. § 314.94. (2024). Content and format of an abbreviated new drug application.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	01116071	Jul 02, 2001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1273292	⤷ Start Trial	C01273292/01	Switzerland	⤷ Start Trial
Austria	267591	⤷ Start Trial
Australia	2002319226	⤷ Start Trial
Bulgaria	108475	⤷ Start Trial
Bulgaria	66328	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 7,939,502